Work

Poster: MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera

Year: 2022

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)00978-8

Authors: Naveen Pemmaraju, Andrew Kuykendall, Marina Kremyanskaya, Yelena Ginzburg, Ellen Ritchie, Jason Gotlib, Aaron Gerds, Jeanne Palmer, Frank Valone, Paula O'Connor, Nishit Modi, Suneel Gupta, Ronald Hoffman, Srdan Verstovsek

Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, NewYork–Presbyterian Hospital, Weill Cornell Medical Center, Cleveland Clinic, Mayo Clinic Hospital, Protagonist Therapeutics (United States)

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296964928

FWCI:

Cites:

Cited by:

Related to: 10